✦ LIBER ✦

Current clinical trial design issues in hormone-refractory prostate carcinoma

✍ Scribed by Nicholas J. Vogelzang; E. David Crawford; Anthony Zietman

Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 100 KB
Volume: 82
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19980601)82:11<2093::aid-cncr3>3.0.co;2-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly 1-hour infusion of paclitaxel : C

Weekly 1-hour infusion of paclitaxel : Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

✍ Charu Trivedi; Bruce Redman; Lawrence E. Flaherty; Omer Kucuk; Wei Du; Lance K. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

Taxol in advanced, hormone-refractory ca

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group

✍ Bruce J. Roth; Patrick J. Loehrer; Beow Yong Yeap; George Wilding; Basil Kasimis 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB 👁 2 views

A phase II randomized trial of megestrol

A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate

✍ S. R. Patel; L. K. Kvols; R. G. Hahn; H. Windschitl; R. Levitt; T. Therneau 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 329 KB 👁 2 views